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Fumio Yamazaki, MD,e Noboru Nishiwaki, MD,f Kazuaki Mitsudo, MD,g and Takeshi Kimura, MD,a
on behalf of the CREDO-Kyoto PCI/CABG registry cohort-2 investigators, Kyoto, Hyogo, Iwate, Shizuoka,
Nara, and Kurashiki, Japan
Objective: The impact of statin therapy on cardiovascular outcome in coronary artery disease (CAD) patients with aortic
aneurysm or dissection (AD) is still unclear. The aim of this study was to elucidate the effect of statins at discharge to
improve outcomes in CAD patients with AD.
Methods: Among 14,834 consecutive patients who underwent ﬁrst coronary revascularization in the CREDO-Kyoto PCI/
CABG registry, we identiﬁed 699 patients (4.7%) with AD. The primary outcome measure was deﬁned as a composite of
all-cause death, myocardial infarction, and stroke. The effect of statin therapy was assessed by a Cox proportional hazards
model incorporating clinically relevant factors.
Results: The risk for the primary outcome measure was signiﬁcantly higher in patients with AD (adjusted hazard ratio
[HR], 1.43; 95% conﬁdence interval [CI], 1.23-1.66; P < .0001). In patients with AD, 215 patients (31%) had already
undergone aneurysm repair, and only 274 patients (39%) were treated with statins at discharge. Patients treated with
statins were younger, had higher body mass index, and were more often treated with percutaneous coronary intervention.
Heart failure, anemia, and hemodialysis were more prevalent in patients treated without statins. In patients without AD,
7014 patients (50%) were treated with statins. Patients treated with statins were younger and had higher body mass
index, and more patients were treated for CAD due to myocardial infarction. Heart failure, prior stroke, hemodialysis,
anemia, and malignant disease were more prevalent in patients treated without statins. The use of statins was associated
with lower risk for the primary outcome measure in patients with AD (adjusted HR, 0.71; 95% CI, 0.51-0.99; P[ .045)
as well as in patients without AD (adjusted HR, 0.79; 95% CI, 0.73-0.85; P < .0001). The effect size of statin use was
similar between the patients with AD and those without AD (P interaction [ .69).
Conclusions: CAD patients with AD had signiﬁcantly higher long-term risk for cardiovascular events. Statin therapy was
associated with lower risk for cardiovascular events in patients with CAD with AD as well as in patients without
AD. (J Vasc Surg 2014;60:604-12.)Aortic aneurysm or dissection (AD) often is associated
with other cardiovascular disease, including coronary artery
disease (CAD) and cerebrovascular disease.1,2 CAD isthe Department of Cardiovascular Medicinea and Department of
ardiovascular Surgery,c Graduate School of Medicine, Kyoto University,
yoto; the Division of General Medicine, Department of Internal
edicine, Hyogo College of Medicine, Hyogob; the Department of
ardiovascular Surgery, Iwate Medical University, Iwated; the Division
Cardiovascular Surgery, Shizuoka City Shizuoka Hospital, Shizuokae;
e Division of Cardiovascular Surgery, Nara Hospital, Kinki University
culty of Medicine, Naraf; and the Division of Cardiology, Kurashiki
entral Hospital, Kurashiki.g
study was supported by the Pharmaceuticals and Medical Devices
gency (PMDA) in Japan.
or conﬂict of interest: T.M. reports board membership of Pﬁzer and
ants from Bayer, Eisai, and Japan Tobacco; he receives payment for lec-
res including service on speaker bureaus from Bayer, Eisai, Japan To-
cco, Kowa, Mitsubishi Tanabe, Otsuka, Pﬁzer, and Takeda.
itional material for this article may be found online at www.jvascsurg.org.
rint requests: Takeshi Kimura, MD, Department of Cardiovascular of
edicine, Graduate School of Medicine, Kyoto University, 54 Shogoin
awahara-cho, Sakyo-ku, Kyoto 606-8507, Japan (e-mail: taketaka@
hp.kyoto-u.ac.jp).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2014.03.280highly prevalent with aortic aneurysms3 or aortic dissec-
tions.4 Long-term survival of patients with AD was poor
even if aneurysms were repaired with a surgical5 or endo-
vascular procedure.6,7 Major causes of death in patients
with AD were not necessarily related to aortic events but
were related to nonaortic cardiovascular events.8 However,
patients with AD were undertreated in terms of optimal
medical therapy in preventing cardiovascular events.8,9
There is a paucity of data regarding optimal medical ther-
apy to improve cardiovascular outcome in patients with
AD. In a previous study of patients with abdominal aortic
aneurysms, statins was reported to decrease morbidity
and mortality of aneurysm repair10 and aneurysm expan-
sion before operation.11 Statin therapy has also been estab-
lished as one of the most effective measures for the primary
and secondary prevention of CAD and ischemic stroke.12
However, there is no dedicated randomized controlled
trial or large-scale observational study evaluating the effect
of statins to prevent cardiovascular events in patients
with CAD and AD. Therefore, we evaluated the effect of
statin therapy at hospital discharge after coronary revascu-
larization procedures on long-term cardiovascular out-
comes in CAD patients with AD compared with
patients without AD in a large Japanese observational data-
base of CAD patients who underwent ﬁrst coronary
revascularization.
Fig 1. Study ﬂow chart. CABG, Coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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Study population. The CREDO-Kyoto (Coronary
REvascularization Demonstrating Outcome study in
Kyoto) percutaneous coronary intervention (PCI)/coro-
nary artery bypass grafting (CABG) registry cohort-2 is a
physician-initiated noncompany-sponsored multicenter
registry enrolling consecutive patients undergoing ﬁrst
coronary revascularization among 26 centers in Japan be-
tween January 2005 and December 2007. The relevant ethics
committees in all 26 participating centers (Appendix A)
approved the research protocol. Because of retrospective
enrollment, written informed consents from the patients were
waived; however, we excluded those patients who refused
participation in the study when they were contacted for
follow-up.
The study design and patient enrollment of the registry
were previously described in detail.13 Among 15,939
patients who underwent ﬁrst coronary revascularization
during the study period, the current study population con-
sisted of 14,834 patients (PCI, 12,716 patients; CABG,
2118 patients), excluding those patients with refusal for
study participation (99 patients), concomitant noncoronary
surgery (609 patients), and in-hospital death (397 patients)
(Fig 1). In-hospital death was deﬁned as death during
admission for ﬁrst coronary revascularization. According
to the hospital chart, 699 patients had AD and 14,135 pa-
tients did not have AD in the current study population.
Data collection for baseline characteristics. Demo-
graphic, angiographic, and procedural data were collected
from hospital charts according to prespeciﬁed deﬁnitions
(Supplementary Methods, online only) by the experi-
enced research coordinators in the independent research
organization (Research Institute for Production Develop-
ment, Kyoto, Japan; Appendix B). Patients with AD wereidentiﬁed by the information recorded in the hospital
charts. Patients with AD were further subdivided into the
two groups of patients with or without surgical or endo-
vascular repair of the AD. Deﬁnitions for other clinical
characteristics are described in the supplemental material.
Information on statin therapy at hospital discharge after
coronary revascularization procedures was also identiﬁed
by the hospital charts.
End points. The primary outcome measure in the
current analysis was deﬁned as a composite of all-cause
death, myocardial infarction (MI), and stroke. Other
prespeciﬁed end points included all-cause death, cardio-
vascular death, noncardiovascular death, MI, stroke, and
any coronary revascularization. Death was regarded as
cardiac in origin unless obvious noncardiac causes could
be identiﬁed. Aneurysm-related death was deﬁned as
death from aneurysm rupture or postoperative death after
aneurysm repair. MI was deﬁned according to the deﬁ-
nition in the Arterial Revascularization Therapy Study.14
Stroke during follow-up was deﬁned as ischemic or
hemorrhagic stroke requiring hospitalization with symp-
toms lasting >24 hours.
Data collection for follow-up events. Collection of
follow-up information was mainly conducted through re-
view of inpatient and outpatient hospital charts by the
clinical research coordinators in the independent research
organization. Additional follow-up information was
collected through contact with patients, relatives, or
referring physicians by mail with questionnaires regarding
vital status, additional hospitalizations, and status of anti-
platelet therapy. Death, MI, and stroke were adjudicated
by the clinical event committee (Appendix C). Median
follow-up duration for surviving patients was 1876 (inter-
quartile range, 1583-2196) days.
Table I. Comparison of baseline characteristics between patients with aortic aneurysm or dissection (AD) and those
without AD
With AD (n ¼ 699) Without AD (n ¼ 14,135) P value
Clinical characteristics
Age, years 73.6 6 8.0 67.8 6 10.8 <.0001
Age $75 yearsa 363 (52) 4108 (29) <.0001
Malea 559 (80) 10210 (72) <.0001
BMI 23.1 6 3.4 23.7 6 3.4 <.0001
BMI <25.0a 531 (76) 9620 (68) <.0001
Acute MIa 105 (15) 4472 (32) <.0001
Total cholesterol, mg/dL 184.7 6 38.0 189.8 6 40.6 .001
HDL cholesterol, mg/dL 45.0 6 12.9 47.5 6 13.4 <.0001
LDL cholesterol, mg/dL 116.1 6 33.7 117.7 6 35.2 .32
Triglyceride, mg/dL 127.2 6 71.5 129.6 6 89.4 .51
Hypertensiona 604 (86) 11632 (82) .005
Diabetes mellitusa 139 (20) 5701 (40) <.0001
Insulin therapy 16 (2.3) 1299 (9.2) <.0001
Current smokinga 194 (28) 4428 (31) .047
Heart failurea 101 (14) 2706 (19) .002
Ejection fraction #40% 63 (11) 1251 (10) .95
Mitral regurgitation grade 3/4a 25 (3.6) 523 (3.7) .87
Prior MIa 92 (13) 1671 (12) .29
Prior stroke (symptomatic)a 132 (19) 1489 (11) <.0001
Peripheral artery diseasea 82 (12) 748 (5.3) <.0001
eGFR <30, without hemodialysisa 50 (7.2) 558 (4.0) <.0001
Hemodialysisa 18 (2.6) 550 (3.9) .08
Atrial ﬁbrillation 85 (12) 1334 (9.4) .02
Anemia (hemoglobin <11.0 g/dL)a 119 (17) 1694 (12) <.0001
Thrombocytopenia (platelet <10*104)a 16 (2.3) 201 (1.4) .06
COPDa 28 (4.2) 487 (3.5) .43
Liver cirrhosisa 22 (3.2) 377 (2.7) .44
Malignant diseasea 100 (14) 1265 (9.0) <.0001
Procedural characteristics
PCI 532 (76) 12184 (86) <.0001
Number of target lesions 1.6 6 0.7 1.5 6 0.7 <.0001
Target of proximal LADa 421 (60) 8584 (61) .79
Unprotected LMCAa 25 (4.7) 393 (3.2) .06
Target of CTOa 145 (21) 2212 (16) .0003
Emergency procedure 130 (19) 4885 (35) <.0001
Medications at discharge
Antiplatelet therapy
Thienopyridines 528 (76) 12090 (86) <.0001
Ticlopidine 471 (89) 10910 (90)
Clopidogrel 57 (11) 1149 (9.5)
Aspirin 685 (98) 13983 (99) .02
Cilostazola 92 (13) 2486 (18) .003
Other medications
Statinsa 274 (39) 7014 (50) <.0001
Beta blockersa 199 (28) 4290 (30) .29
ACE-I/ARBa 334 (48) 7870 (56) <.0001
Nitratesa 251 (36) 5081 (36) .98
Calcium channel blockersa 376 (54) 5917 (42) <.0001
Nicorandila 160 (23) 3779 (27) .02
Warfarina 100 (14) 1759 (12) .15
Proton pump inhibitorsa 193 (28) 3964 (28) .8
H2 blockers
a 194 (28) 3893 (28) .9
ACE-I, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease;
CTO, chronic total occlusion; eGFR, estimated glomerular ﬁltration rate;H2 blockers, histamine type 2 receptor blockers;HDL, high-density lipoprotein; LAD,
left anterior descending coronary artery; LDL, low-density lipoprotein; LMCA, left main coronary artery; MI, myocardial infarction; PCI, percutaneous
coronary intervention.
Continuous data are presented as mean 6 standard deviation and categorical data as number (%). Values were missing for BMI in 377 patients, for total
cholesterol in 596 patients, for HDL cholesterol in 2274 patients, for LDL cholesterol in 2797 patients, and for triglyceride in 1466 patients.
aRisk adjustment variables selected for Cox proportional hazards model.
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Fig 2. Kaplan-Meier event curves: patients with vs without aortic
aneurysm or dissection (AD) for a composite of all-cause death,
myocardial infarction (MI), and stroke. The estimated event-free
survival 6 standard error was 90% 6 1.1% in the AD group vs
93% 6 0.2% in the no AD group at 1 year, 82% 6 1.5% vs 90% 6
0.3% at 2 years, 78%6 1.6% vs 86%6 0.3% at 3 years, 72%6 1.8%
vs 82% 6 0.3% at 4 years, and 65% 6 1.9% vs 78% 6 0.4% at
5 years (P < .0001), respectively.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 3 Tazaki et al 607Statistical analysis. Categorical variables were pre-
sented as number and percentage and were compared
with the c2 test. Continuous variables were expressed as
mean value6 standard deviation or median with interquar-
tile range. Continuous variables were compared by the Stu-
dent t-test or Wilcoxon rank sum test on the basis of their
distributions.
The cumulative incidence of clinical events was esti-
mated by the Kaplan-Meier method, and differences were
assessed with the log-rank test. We estimated the adjusted
risk of AD relative to no AD by the Cox proportional haz-
ards model, adjusting for 32 clinically relevant factors.
Continuous variables were dichotomized by clinically
meaningful reference values or median values. Proportional
hazard assumptions for potential independent risk adjust-
ment variables were assessed on the plots of log (time) vs
log [log (survival)] stratiﬁed by the variable, and the as-
sumptions were veriﬁed to be acceptable for all the vari-
ables. Center was included in the model as the
stratiﬁcation variable. The effects of AD for individual
end points were expressed as hazard ratios (HRs) and their
95% conﬁdence intervals (CIs). The effect of statin therapy
was assessed by a Cox proportional hazards model incorpo-
rating 12 variables to avoid overﬁtting because the total
number of primary end point events in the AD group
was too small to adjust all covariates used in the analyses
of all patients. We thus selected the 12 variables with P
values < .05 from the univariate Cox proportional hazards
model (Supplementary Table, online only).
Statistical analyses were conducted by a physician (J.T.)
and a statistician (T.M.) with the use of JMP 8.0 (SAS
Institute Inc, Cary, NC) software and SAS 9.2 (SAS Insti-
tute Inc). All the statistical analyses were two tailed, and P
values < .05 were considered statistically signiﬁcant.
RESULTS
Baseline characteristics and clinical outcomes: AD
vs no AD. Signiﬁcant differences were observed in many
variables in the baseline clinical characteristics between
the two groups of patients with or without AD (Table I).
Patients with AD were older and more often had male
gender, smaller body mass index, hypertension, prior
stroke, peripheral artery disease, end-stage renal disease not
on hemodialysis, anemia, atrial ﬁbrillation, and malignant
disease. On the other hand, patients without AD more
often had acute coronary syndrome, heart failure, diabetes,
and current smoking.
Regarding lesion and procedural characteristics, pa-
tients with AD more often had multivessel CAD, target
of chronic total occlusion lesion, and greater numbers of
target lesions or anastomoses. Patients without AD more
often had emergency procedures and target of proximal
left anterior descending coronary artery lesion. Baseline
medications were also signiﬁcantly different between the
two groups. Despite the higher risk proﬁle of patients
with AD, statins were used less frequently in patients
with AD than in patients without AD (39% vs 50%; P <
.0001). Patients with AD received calcium channelblockers more often and angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers less often.
The cumulative incidence of primary outcome was
signiﬁcantly higher in patients with AD than in those
without AD (35% vs 22%; log-rank, P < .0001; Fig 2).
Adjusted risk for the primary outcome measure was signif-
icantly higher in patients with AD (adjusted HR, 1.43; 95%
CI, 1.23-1.66; P < .0001; Table II), and the risks for all-
cause death, cardiovascular death, noncardiovascular death,
and stroke were also signiﬁcantly higher in patients with
AD than in those without AD. However, the risks for MI
and any coronary revascularization were not signiﬁcantly
different between the two groups. Aneurysm-related death
was observed in 25 patients (7.2%) with AD and 17 pa-
tients (0.2%) without AD.
Among 699 patients with AD, 215 patients (31%) had
already undergone surgical or endovascular repair of the
AD, whereas 484 patients (69%) had not undergone repair
before the index coronary revascularization. During follow-
up after coronary revascularization, 188 (27%) patients
with AD underwent aortic repair because of aneurysm
expansion or dissection. The cumulative incidence of the
Table II. Five-year clinical outcomes in patients with aortic aneurysm or dissection (AD) vs without AD
With AD (n ¼ 699),
No. (%)
Without AD (n ¼ 14,135),
No. (%)
Univariate
HR (95% CI) P value
Multivariable
HR (95% CI) P value
Death/MI/stroke 231 (35) 2876 (22) 1.75 (1.54-1.99) <.0001 1.43 (1.23-1.66) <.0001
Death 179 (27) 1941 (15) 2.00 (1.73-2.30) <.0001 1.53 (1.29-1.81) <.0001
Cardiovascular death 101 (16) 934 (7.3) 2.32 (1.91-2.81) <.0001 1.87 (1.48-2.36) <.0001
Noncardiovascular death 78 (13) 1007 (8.0) 1.69 (1.36-2.09) <.0001 1.27 (0.99-1.62) .06
MI 27 (4.5) 590 (4.6) 0.95 (0.64-1.35) .78 0.95 (0.62-1.44) .79
Stroke 72 (12) 805 (6.3) 1.91 (1.50-2.39) <.0001 1.59 (1.20-2.10) .001
Any coronary
revascularization
172 (28) 4386 (33) 0.77 (0.66-0.89) .0004 0.93 (0.79-1.10) .42
CI, Conﬁdence interval; HR, hazard ratio; MI, myocardial infarction.
Cumulative incidences of clinical end points at 5 years were estimated by the Kaplan-Meier method.
Fig 3. Kaplan-Meier event curves: Patients with vs without repair
of aortic aneurysm or dissection (AD) aortic disease for a com-
posite of all-cause death, myocardial infarction (MI), and stroke.
The estimated event-free survival 6 standard error was 93% 6
1.8% in the group with repair vs 88% 6 1.5% in the group without
repair at 1 year, 84%6 2.5% vs 81%6 1.8% at 2 years, 79%6 2.8%
vs 77% 6 1.9% at 3 years, 74% 6 3.0% vs 71% 6 2.1% at 4 years,
and 67%6 3.3% vs 64%6 2.3% at 5 years (P ¼ .72), respectively.
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groups of patients with or without surgical or endovascular
repair of the AD (33% vs 36%; log-rank, P ¼ .72; Fig 3).
Baseline characteristics and clinical outcomes: Sta-
tins vs no statins. In patients with AD who underwent
coronary revascularization, statins were prescribed in only
274 patients (39%) at hospital discharge (Table III).
Patients treated with statins were younger, were more often
treated with PCI, and had greater body mass index. Pa-
tients treated with statins were also more often treated with
beta blockers and angiotensin-converting enzyme in-
hibitors or angiotensin receptor blockers. Heart failure, low
ejection fraction, anemia, hemodialysis, and nitrate use
were more prevalent in patients treated without statins. In
patients without AD, 7014 patients (50%) were treated
with statins at hospital discharge. Signiﬁcant differences
were also observed in many variables in the baseline clinical
characteristics between the two groups of patients treated
with or without statins (Table IV). Patients treated with
statins were younger, had greater body mass index, and had
more MI and current smoking. Heart failure, prior stroke,
peripheral artery disease, hemodialysis, anemia, thrombo-
cytopenia, and malignant disease were more prevalent in
patients treated without statins.
The cumulative incidence of the primary outcome
measure was signiﬁcantly lower in the statins group than
in the no statins group regardless of the presence of AD
(AD: 29% vs 39%; P ¼ .002; no AD: 17% vs 26%; P <
.0001; Fig 4). After adjustment for confounders, the use
of statins was associated with lower risk for the primary
outcome measure in patients with AD (adjusted HR,
0.71; 95% CI, 0.51-0.99; P ¼ .045; Table V) as well as
in patients without AD (adjusted HR, 0.79; 95% CI,
0.73-0.85; P < .0001; Table VI). The effect size of statin
use was similar between the patients with AD and without
AD (P interaction ¼ .69). In 215 patients with AD that
was already repaired at coronary revascularization, the cu-
mulative incidence of the primary outcome measure at
5 years tended to be lower in the group receiving statins
(28% in the statin group vs 37% in the no statin group;
log-rank, P ¼ .14). In 188 patients with AD that was
repaired after coronary revascularization, the cumulativeincidence of the primary outcome measure at 5 years was
similar between the two groups (29% in the statin group
vs 31% in the no statin group; log-rank, P ¼ .51). In 309
patients with AD that was not repaired before or after cor-
onary revascularization, the cumulative incidence of the
primary outcome measure at 5 years was lower in the group
Table III. Comparison of baseline characteristics
between statin and no statin groups in patients with aortic
aneurysm or dissection (AD)
Statin
(n ¼ 274)
No statin
(n ¼ 425) P value
Clinical characteristics
Age, years 72.3 6 8.5 74.4 6 7.7 .0007
Age $75 yearsa 128 (47) 235 (55) .03
Male 210 (77) 349 (82) .08
BMI 23.7 6 3.4 22.6 6 3.3 <.0001
BMI <25.0a 189 (69) 342 (80) .0005
Acute MIa 42 (15) 63 (15) .86
Hypertension 246 (90) 358 (84) .04
Diabetes mellitus 59 (22) 80 (19) .38
Insulin therapy 6 (2.2) 10 (2.4) .89
Current smoking 71 (26) 123 (29) .38
Heart failurea 29 (11) 72 (17) .02
Ejection fraction #40% 16 (6.7) 47 (13) .01
Mitral regurgitation
grade 3/4
10 (3.7) 15 (3.5) .93
Prior MIa 33 (12) 59 (14) .48
Prior stroke (symptomatic)a 51 (19) 81 (19) .88
Peripheral artery disease 33 (12) 49 (12) .84
eGFR <30,without
hemodialysisa
16 (5.8) 34 (8.0) .28
Hemodialysisa 2 (0.7) 16 (3.8) .01
Atrial ﬁbrillation 26 (9.5) 59 (14) .08
Anemia (hemoglobin
<11.0 g/dL)a
33 (12) 86 (20) .005
Thrombocytopenia
(platelet <10*104)a
4 (1.5) 12 (2.8) .24
COPD 9 (3.3) 19 (4.5) .44
Liver cirrhosis 5 (1.8) 17 (4.0) .11
Malignant diseasea 38 (14) 62 (15) .79
Procedural characteristics
PCI 225 (82) 307 (72) .003
Number of target lesions 1.5 6 0.7 1.6 6 0.8 .03
Target of proximal LAD 159 (58) 262 (62) .34
Unprotected LMCAa 13 (5.8) 12 (3.9) .31
Target of CTO 53 (19) 92 (22) .46
Emergency procedure 51 (19) 79 (19) .99
Medications at discharge
Antiplatelet therapy
Thienopyridines 228 (83) 300 (71) .0002
Ticlopidine 201 (88) 271 (90)
Clopidogrel 28 (12) 29 (9.7)
Aspirin 270 (99) 415 (98) .41
Cilostazol 35 (13) 57 (13) .81
Other medications
Beta blockers 97 (35) 102 (24) .001
ACE-I/ARB 149 (54) 185 (44) .005
Nitrates 83 (30) 168 (40) .01
Calcium channel blockers 152 (55) 224 (53) .47
Nicorandil 64 (23) 96 (23) .81
Warfarin 30 (11) 70 (16) .04
Proton pump inhibitors 75 (27) 118 (28) .91
H2 blockers 77 (28) 117 (28) .87
ACE-I, Angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; BMI, body mass index; COPD, chronic obstructive pul-
monary disease; CTO, chronic total occlusion; eGFR, estimated glomerular
ﬁltration rate; H2 blockers, histamine type 2 receptor blockers; LAD, left
anterior descending coronary artery; LMCA, left main coronary artery; MI,
myocardial infarction; PCI, percutaneous coronary intervention.
Continuous data are presented as mean 6 standard deviation and cate-
gorical data as number (%).
aRisk adjustment variables selected for Cox proportional hazards model.
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statin group; log-rank, P ¼ .01).
DISCUSSION
The main ﬁndings of this analysis were the following:
patients with AD compared with those without AD had
signiﬁcantly higher long-term risk for cardiovascular
events; and statin therapy in patients with AD was asso-
ciated with a lower risk for cardiovascular events, with
an effect size similar to that observed in patients
without AD.
In the current study, we focused on the unique pop-
ulation of patients with CAD and AD who underwent
coronary revascularization. CAD patients who could
not undergo coronary revascularization were not
included. Some of the patients with AD had already
been repaired, some underwent aneurysm repair after
coronary revascularization, and some had a diagnosis
only. In this analysis, the long-term cardiovascular event
risk of CAD patients with AD was signiﬁcantly higher
than that of those without AD. Patients with AD were
older and more often had a history of stroke, carotid ar-
tery stenosis, and complex CAD, suggesting that
advanced atherosclerosis might be one of the underlying
reasons for the poor prognosis of patients with AD.1,8
We previously reported that clinical outcome after coro-
nary revascularization was worse in patients with polyvas-
cular disease compared with patients with CAD alone,
which was mainly driven by the increased risk of non-
coronary vascular events.15 In the current study, the
higher risk of patients with AD for cardiovascular events
was also driven by the increased risk for noncoronary car-
diovascular events. In addition, the cumulative incidence
of death, MI, or stroke was not different between the
two groups of patients with or without repair of AD.
AD remains associated with higher risk for cardiovascular
events, even if AD has been treated with either surgical
or endovascular procedures. Therefore, physicians and
surgeons should pay more attention to the secondary
prevention of cardiovascular events in patients with AD
irrespective of repair status.
Patients with AD were undertreated in terms of
optimal medical therapy for preventing cardiovascular
events.16,17 In the current study, statins were prescribed
less frequently after coronary revascularization in patients
with AD than in those without AD, despite their demo-
graphics suggesting association with more advanced
atherosclerotic disease. Statin therapy has been established
as one of the most effective measures for the primary
and secondary prevention of CAD and ischemic stroke.12
However, the protective effect of statins could not be
demonstrated in those randomized controlled trials
focusing on patients with advanced atherosclerosis, such
as patients with hemodialysis and end-stage heart fail-
ure.18-20 Although patients with AD also have more
advanced atherosclerosis than patients without AD,1 there
is no dedicated randomized controlled trial or large-scale
Table IV. Comparison of baseline characteristics
between statin and no statin groups in patients without
aortic aneurysm or dissection (AD)
Statin
(n ¼ 7014)
No statin
(n ¼ 7121) P value
Clinical characteristics
Age, years 66.4 6 10.9 69.1 6 10.6<.0001
Age $75 yearsa 1754 (25) 2354 (33) <.0001
Male 4877 (70) 5333 (75) <.0001
BMI 24.3 6 3.5 23.2 6 3.4 <.0001
BMI <25.0a 4410 (63) 5210 (73) <.0001
Acute MIa 2440 (35) 2032 (29) <.0001
Hypertension 5865 (84) 5767 (81) <.0001
Diabetes mellitus 2824 (40) 2877 (40) .86
Insulin therapy 575 (8.2) 724 (10) <.0001
Current smoking 2295 (33) 2133 (30) .0004
Heart failurea 1133 (16) 1573 (22) <.0001
Ejection fraction #40% 525 (8.7) 726 (12) <.0001
Mitral regurgitation
grade 3/4
200 (2.9) 323 (4.5) <.0001
Prior MIa 798 (11) 873 (12) .10
Prior stroke
(symptomatic)a
610 (8.7) 879 (12) <.0001
Peripheral artery disease 297 (4.2) 451 (6.3) <.0001
eGFR <30,without
hemodialysisa
213 (3.0) 345 (4.8) <.0001
Hemodialysisa 115 (1.6) 435 (6.1) <.0001
Atrial ﬁbrillation 499 (7.1) 835 (12) <.0001
Anemia (hemoglobin
<11.0 g/dL)a
571 (8.1) 1123 (16) <.0001
Thrombocytopenia
(platelet <10*104)a
57 (0.8) 144 (2.0) <.0001
COPD 239 (3.4) 248 (3.5) .81
Liver cirrhosis 129 (1.8) 248 (3.5) <.0001
Malignant diseasea 520 (7.4) 745 (10) <.0001
Procedural characteristics
PCI 6431 (92) 5753 (81) <.0001
Number of target lesions 1.4 6 0.6 1.5 6 0.7 <.0001
Target of proximal LAD 4192 (60) 4392 (62) .02
Unprotected LMCAa 199 (3.1) 194 (3.4) .39
Target of CTO 993 (14) 1219 (17) <.0001
Emergency procedure 2633 (38) 2252 (32) <.0001
Medications at discharge
Antiplatelet therapy
Thienopyridines 6365 (91) 5725 (80) <.0001
Ticlopidine 5624 (89) 5286 (93)
Clopidogrel 722 (11) 427 (7.5)
Aspirin 6957 (99.2) 7026 (98.7) .003
Cilostazol 1136 (19) 1150 (16) <.0001
Other medications
Beta blockers 2463 (35) 1827 (26) <.0001
ACE-I/ARB 4317 (62) 3553 (50) <.0001
Nitrates 2276 (32) 2805 (40) <.0001
Calcium channel blockers 2801 (40) 3116 (44) <.0001
Nicorandil 1836 (26) 1943 (27) <.0001
Warfarin 703 (10) 1056 (15) <.0001
Proton pump inhibitors 1942 (28) 2022 (28) .35
H2 blockers 1957 (28) 1936 (27) .34
ACE-I, Angiotensin-converting enzyme inhibitor; ARB, angiotensin re-
ceptor blocker; BMI, body mass index; COPD, chronic obstructive pul-
monary disease; CTO, chronic total occlusion; eGFR, estimated glomerular
ﬁltration rate; H2 blockers, histamine type 2 receptor blockers; LAD, left
anterior descending coronary artery; LMCA, left main coronary artery; MI,
myocardial infarction; PCI, percutaneous coronary intervention.
Continuous data are presented as mean 6 standard deviation and cate-
gorical data as number (%).
aRisk adjustment variables selected for Cox proportional hazards model.
Fig 4. Kaplan-Meier event curves: statins vs no statins in patients
with aortic aneurysm and dissection (AD) and without AD for a
composite of all-cause death, myocardial infarction (MI), and
stroke. The estimated event-free survival 6 standard error was
87% 6 1.7% in the AD(þ) Statin() group vs 95% 6 1.3% in the
AD(þ) Statin(þ) group vs 92% 6 0.3% in the AD() Statin()
group vs 95% 6 0.3% in the AD() Statin(þ) at 1 year, 79% 6
2.0% vs 87% 6 2.0% vs 88% 6 0.4% vs 92% 6 0.3% at 2 years,
73% 6 2.2% vs 85% 6 2.2% vs 83% 6 0.5% vs 89% 6 0.4% at
3 years, 68% 6 2.3% vs 78% 6 2.5% vs 79% 6 0.5% vs 86% 6 0.4%
at 4 years, and 61% 6 2.5% vs 71% 6 2.9% vs 74% 6 0.5% vs
83% 6 0.5% at 5 years, respectively.
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effect of statins in patients with AD. In previous studies,
statins were reported to decrease morbidity and mortality
of aneurysm repair in patients with abdominal aortic aneu-
rysm10 and aneurysm expansion before operation.11 Statins
also improved survival outcome after surgical repair of
aortic aneurysm.9,16 Aortic aneurysms also have aspects of
more extensive vascular inﬂammation in addition to
advanced atherosclerosis.1,21-23 Statins are reported to
improve biomarker levels of vascular inﬂammation in pa-
tients with atherosclerosis.24,25 In the current study, statin
therapy in patients with AD was associated with a lower risk
for cardiovascular events with an effect size similar to that
observed in patients without AD. Statin effect was also
observed in patients with AD that was not repaired before
or after coronary revascularization. Therefore, atheroscle-
rosis in patients with AD might be qualitatively different
Table V. Five-year clinical outcomes in patients with aortic aneurysm or dissection (AD): Statin therapy vs no statin
therapy
Statin þ (n ¼ 274),
No. (%)
Statin  (n ¼ 425),
No. (%)
Univariate
HR (95% CI) P value
Multivariable
HR (95% CI) P value
Death/MI/stroke 74 (29) 157 (39) 0.66 (0.51-0.86) .002 0.71 (0.51-0.99) .045
Death 57 (22) 122 (31) 0.68 (0.50-0.91) .01 0.71 (0.42-1.20) .13
Cardiovascular death 28 (11) 73 (19) 0.53 (0.34-0.79) .002 0.83 (0.51-1.34) .20
Noncardiovascular death 29 (12) 49 (14) 0.92 (0.59-1.40) .69 0.78 (0.45-1.37) .39
MI 9 (4.2) 18 (4.8) 0.67 (0.29-1.44) .32 0.58 (0.21-1.65) .31
Stroke 19 (7.9) 53 (14) 0.53 (0.31-0.86) .009 0.81 (0.45-1.44) .47
Any coronary revascularization 75 (30) 97 (26) 1.20 (0.89-1.62) .23 1.20 (0.84-1.71) .31
CI, Conﬁdence interval; HR, hazard ratio; MI, myocardial infarction.
Incidences of clinical end points at 5 years were estimated by the Kaplan-Meier method.
Table VI. Five-year clinical outcomes in patients without aortic aneurysm or dissection (AD): Statin therapy vs no statin
therapy
Statin þ (n ¼ 7014),
No. (%)
Statin  (n ¼ 7121),
No. (%)
Univariate
HR (95% CI) P value
Multivariable
HR (95% CI) P value
Death/MI/stroke 1143 (17) 1733 (26) 0.64 (0.60-0.69) <.0001 0.79 (0.73-0.85) <.0001
Death 700 (11) 1241 (19) 0.55 (0.51-0.60) <.0001 0.75 (0.68-0.83) <.0001
Cardiovascular death 325 (5.1) 606 (9.4) 0.54 (0.48-0.61) <.0001 0.79 (0.68-0.91) .001
Noncardiovascular death 372 (5.8) 635 (10) 0.57 (0.50-0.64) <.0001 0.72 (0.63-0.82) <.0001
MI 286 (4.4) 304 (4.8) 0.92 (0.79-1.08) .32 0.93 (0.79-1.11) .43
Stroke 330 (5.1) 475 (7.5) 0.69 (0.61-0.79) <.0001 0.82 (0.70-0.96) .01
Any coronary
revascularization
2208 (33) 2178 (33) 1.0005 (0.94-1.06) .99 0.95 (0.89-1.008) .09
CI, Conﬁdence interval; HR, hazard ratio; MI, myocardial infarction.
Incidences of clinical end points at 5 years were estimated by the Kaplan-Meier method.
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alysis and end-stage heart failure.
There are several important limitations in this study.
First and most important, the observational study design
precluded deﬁnitive conclusions to be drawn about the ef-
ﬁcacy of statins because of selection bias and unmeasured
confounders. Second, we did not have data on the duration
of and adherence to the statin therapy during follow-up.
Finally, we did not have data on the types of aneurysm
or dissection and locations of AD (thoracic, thoracoabdo-
minal, or abdominal).
CONCLUSIONS
CAD patients with AD compared with those without
AD had signiﬁcantly higher long-term risk for cardiovascu-
lar events. Statin therapy in patients with AD was associated
with lower risk for cardiovascular events with an effect size
similar to that observed in patients without AD.
We appreciate the support and collaboration of the co-
investigators participating in the CREDO-Kyoto PCI/
CABG Registry Cohort-2. We are indebted to the
outstanding effort of the clinical research coordinators for
data collection.
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Deﬁnitions for clinical characteristics. Baseline clin-
ical characteristics, such as prior myocardial infarction,
heart failure, hypertension, current smoking, atrial ﬁbrilla-
tion, chronic obstructive lung disease, liver cirrhosis, and
malignant disease, were regarded as present when these di-
agnoses were recorded in the hospital charts. Elderly
patients were deﬁned as those patients $75 years of age.
Unstable angina was deﬁned as Braunwald classiﬁcation
type 3. Diabetes was deﬁned as treatment with oral hypo-
glycemic agents or insulin, prior clinical diagnosis of
diabetes, glycated hemoglobin level $6.5%, or blood
glucose level $200 mg/dL. Blood glucose test results in
the acute phase of acute myocardial infarction were not
used for the diagnosis of diabetes. Prior stroke included
both ischemic and hemorrhagic stroke and was deﬁned as
stroke with neurologic symptoms lasting >24 hours. Pe-
ripheral vascular disease was regarded as present when ca-
rotid or other peripheral vascular disease was being
treated or scheduled for surgical or endovascular interven-
tions, except for aortic aneurysm or dissection. Left ventric-
ular ejection fraction was measured by either contrast left
ventriculography or echocardiography. Patients with left
ventricular ejection fraction #40% were regarded as having
left ventricular dysfunction. Renal function was expressed
as estimated glomerular ﬁltration rate, calculated by the
Modiﬁcation of Diet in Renal Disease formula modiﬁed
for Japanese patients.1 Anemia was deﬁned as blood he-
moglobin level <11.0 g/dL. Thrombocytopenia was
deﬁned as platelet count <100  109/L. Baseline medi-
cations were regarded as present if they were prescribed
during the index hospitalization.
REFERENCE
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APPENDIX A
Participating centers and the investigators for the
CREDO-Kyoto PCI/CABG Registry Cohort-2
Cardiology. Kyoto University Hospital: Takeshi
Kimura
Kishiwada City Hospital: Mitsuo Matsuda, Hirokazu
Mitsuoka
Tenri Hospital: Yoshihisa Nakagawa
Hyogo Prefectural Amagasaki Hospital: Hisayoshi
Fujiwara, Yoshiki Takatsu, Ryoji Taniguchi
Kitano Hospital: Ryuji Nohara
Koto Memorial Hospital: Tomoyuki Murakami, Ter-
uki Takeda
Kokura Memorial Hospital: Masakiyo Nobuyoshi,
Masashi Iwabuchi
Maizuru Kyosai Hospital: Ryozo Tatami
Nara Hospital, Kinki University Faculty of Medicine:
Manabu ShirotaniKobe City Medical Center General Hospital: Toru
Kita, Yutaka Furukawa, Natsuhiko Ehara
Nishi-Kobe Medical Center: Hiroshi Kato, Hiroshi
Eizawa
Kansai Denryoku Hospital: Katsuhisa Ishii
Osaka Red Cross Hospital: Masaru Tanaka
University of Fukui Hospital: Jong-Dae Lee, Akira
Nakano
Shizuoka City Shizuoka Hospital: Akinori Takizawa
Hamamatsu Rosai Hospital: Masaaki Takahashi
Shiga University of Medical Science Hospital: Minoru
Horie, Hiroyuki Takashima
Japanese Red Cross Wakayama Medical Center: Taka-
shi Tamura
Shimabara Hospital: Mamoru Takahashi
Kagoshima University Medical and Dental Hospital:
Chuwa Tei, Shuichi Hamasaki
Shizuoka General Hospital: Hirofumi Kambara,
Osamu Doi, Satoshi Kaburagi
Kurashiki Central Hospital: Kazuaki Mitsudo, Kazush-
ige Kadota
Mitsubishi Kyoto Hospital: Shinji Miki, Tetsu Mizoguchi
Kumamoto University Hospital: Hisao Ogawa, Seigo
Sugiyama
Shimada Municipal Hospital: Ryuichi Hattori, Takeshi
Aoyama, Makoto Araki
Juntendo University Shizuoka Hospital: Satoru Suwa
Cardiovascular Surgery. Kyoto University Hospital:
Ryuzo Sakata, Tadashi Ikeda, Akira Marui
Kishiwada City Hospital: Masahiko Onoe
Tenri Hospital: Kazuo Yamanaka
Hyogo Prefectural Amagasaki Hospital: Keiichi Fuji-
wara, Nobuhisa Ohno
Kokura Memorial Hospital: Michiya Hanyu
Maizuru Kyosai Hospital: Tsutomu Matsushita
Nara Hospital, Kinki University Faculty of Medicine:
Noboru Nishiwaki, Yuichi Yoshida
Kobe City Medical Center General Hospital: Yukikatsu
Okada, Michihiro Nasu
Osaka Red Cross Hospital: Shogo Nakayama
University of Fukui Hospital: Kuniyoshi Tanaka,
Takaaki Koshiji, Koichi Morioka
Shizuoka City Shizuoka Hospital: Mitsuomi Shima-
moto, Fumio Yamazaki
Hamamatsu Rosai Hospital: Junichiro Nishizawa
Japanese Red Cross Wakayama Medical Center:
Masaki Aota
Shimabara Hospital: Takafumi Tabata
Kagoshima University Medical and Dental Hospital:
Yutaka Imoto, Hiroyuki Yamamoto
Shizuoka General Hospital: Katsuhiko Matsuda, Masa-
fumi Nara
Kurashiki Central Hospital: Tatsuhiko Komiya
Mitsubishi Kyoto Hospital: Hiroyuki Nakajima
Kumamoto University Hospital: Michio Kawasuji,
Syuji Moriyama
Juntendo University Shizuoka Hospital: Keiichi
Tanbara
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Clinical research coordinators
Research Institute for Production Development.
Kumiko Kitagawa, Misato Yamauchi, Naoko Okamoto,
Yumika Fujino, Saori Tezuka, Asuka Saeki, Miya Hana-
zawa, Yuki Sato, Chikako Hibi, Hitomi Sasae, Emi Taki-
nami, Yuriko Uchida, Yuko Yamamoto, Satoko Nishida,
Mai Yoshimoto, Sachiko Maeda, Izumi Miki, Saeko
MinematsuSupplementary Table (online only). Hazard ratios (HRs) fo
myocardial infarction [MI]/stroke) in patients with aortic aneu
Clinical characteristics
Age $75 yearsa
Male
BMI <25.0a
Acute MIa
Hypertension
Diabetes mellitus
Current smoking
Heart failurea
Mitral regurgitation grade 3/4
Prior MIa
Prior stroke (symptomatic)a
Peripheral artery disease
eGFR <30,without hemodialysisa
Hemodialysisa
Atrial ﬁbrillation
Anemia (hemoglobin <11.0 g/dL)a
Thrombocytopenia (platelet <10*104)a
COPD
Liver cirrhosis
Malignant diseasea
Procedural characteristics
PCI
Number of target lesions
Target of proximal LAD
Unprotected LMCAa
Target of CTO
Emergency procedure
Baseline medications
Antiplatelet therapy
Thienopyridines
Aspirin
Cilostazol
Other medications
Beta blockers
ACE-I/ARB
Nitrates
Calcium channel blockers
Nicorandil
Warfarin
Proton pump inhibitors
H2 blockers
ACE-I, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
obstructive pulmonary disease; CTO, chronic total occlusion; eGFR, estimated glo
left anterior descending coronary artery; LMCA, left main coronary artery; PCI,
aRisk adjustment variables selected for Cox proportional hazards model.APPENDIX C
Clinical event committee members. Mitsuru Abe
(Kyoto Medical Center), Hiroki Shiomi (Kyoto University
Hospital), Tomohisa Tada (Deutsches Herzzentrum),
Junichi Tazaki (Kyoto University Hospital), Yoshihiro
Kato (Saiseikai Noe Hospital), Mamoru Hayano (Kyoto
University Hospital), Akihiro Tokushige (Kagoshima Uni-
versity Hospital), Masahiro Natsuaki (Kyoto University
Hospital), Tetsu Nakajima (Kyoto University Hospital)r 5-year primary outcome measure (composite of death/
rysm or dissection (AD)
Univariate
HR (95% CI) P value
1.97 (1.53-2.55) <.0001
1.24 (0.91-1.75) .18
1.63 (1.20-2.26) .002
1.43 (1.04-1.94) .03
1.12 (0.79-1.65) .53
1.23 (0.92-1.64) .16
0.90 (0.68-1.18) .45
2.19 (1.63-2.92) <.0001
1.33 (0.68-2.32) .37
1.68 (1.21-2.29) .002
1.57 (1.18-2.06) .002
1.32 (0.90-1.85) .14
2.50 (1.69-3.57) <.0001
2.81 (1.53-4.72) .002
1.35 (0.94-1.89) .10
1.54 (1.14-2.06) .005
3.27 (1.73-5.59) .0007
1.37 (0.72-2.33) .31
1.18 (0.59-2.11) .61
1.44 (0.04-1.95) .03
1.07 (0.80-1.44) .65
0.99 (0.83-1.16) .86
0.96 (0.75-1.24) .77
2.18 (1.23-3.57) .009
0.76 (0.55-1.04) .09
1.27 (0.93-1.69) .13
1.01 (0.77-1.36) .92
1.55 (0.66-5.02) .35
1.09 (0.76-1.53) .63
1.12 (0.85-1.45) .41
0.97 (0.76-1.24) .79
1.16 (0.90-1.49) .25
1.14 (0.89-1.46) .31
1.25 (0.94-1.64) .12
1.39 (0.99-1.90) .06
1.25 (0.96-1.63) .10
1.08 (0.82-1.41) .57
blocker; BMI, body mass index; CI, conﬁdence interval; COPD, chronic
merular ﬁltration rate; H2 blockers, histamine type 2 receptor blockers; LAD,
percutaneous coronary intervention.
